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cytometry and ADP-induced platelet aggregation (PAG), measured by light trans-
mission aggregometry].
Results: All the subjects were dichotomized according to PRI medians (normal-re-
sponders: PRI<41.85%, n¼45 and low-responders: PRI>41.85%, n¼45) and PAG
medians (normal-responders: PAG<65.5%, n¼49 and low-responders: PAG>65.5%,
n¼41). No signiﬁcant differences of demographic data were found between normal-
and low-responders determined by the two methods. To further explore the potential
clinical characteristics associated with the discrepancy of VASP phosphorylation and
PAG in evaluating platelet reactivity, patients who were normal-responders to both
methods, or who were low-responders to both methods, were deﬁned as “concor-
dance” group (n¼60). Otherwise, the rest patients were deﬁned as “discrepancy
group” (n¼30). Stepwise binary logistic regression analysis revealed that among
factors that potentially inﬂuence the consistency of the two methods, smoking was the
only independent predictor associated with the discrepancy of the two methods (OR
3.333, 95% CI 1.120 to 9.917, P¼0.030). After adjusted by the traditional factors
(age, gender, hypertension and diabetes) that may inﬂuence the responsiveness of
platelets to clopidogrel, smoking remains statistically predict the discrepancy between
these two methods in evaluating platelet reactivity (OR 4.399, 95% CI 1.105 to
17.522, P¼0.036).
Conclusions: The present study shows that smoking is an independent factor that
inﬂuences the consistancy of VASP phosphorylation and ADP-induced PAG in
evaluating high on-clopidogrel platelet reactivity in patients with STEMI.
GW25-e4386
The platelet receptor P2Y12 gene polymorphisms and thrombelastography could
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Objectives: Polymorphisms in the platelet receptor P2Y12 gene have been suggested
to inﬂuence the pharmacodynamics of clopidogrel and prognosis of patients treated
with clopidogrel. The effect of P2Y12 polymorphisms and the prognostic utility of
thrombelastography (TEG) on bleeding events of clopidogrel treatment have not yet
been reported in Chinese patients after percutaneous coronary intervention (PCI). This
study sought to investigate the impact of P2Y12 polymorphisms and the predictive
value of TEG on the risk of bleeding in clopidogrel-treated Chinese patients after PCI.
Methods: Between January 2011 and June 2012, 504 consecutive patients with acute
coronary syndromes (ACS) who received coronary angiography or an uneventful PCI
and were exposed to clopidogrel treatment for 12 months, were enrolled in the single-
center registry. 18 tag single nucleotide polymorphisms (SNPs) selected from P2Y12
gene and the gain of function CYP2C19*17 allele were detected by the ligase
detection reaction. The antiplatelet effect of clopidogrel was assessed by TEG. The
primary clinical safety end point was the incidence of major bleeding deﬁned ac-
cording to the Bleeding Academic Research Consortium (BARC) criteria, including
type 3 and 5 in the analysis. The primary clinical efﬁcacy end point was a composite
of cardiovascular death, non-fatal myocardial infarction, unplanned target vessel
revascularization, and stent thrombosis. The follow-up period was 12 months.
Results: Major bleeding events occurred in 47 patients (9.3%) according to BARC
criteria, including 12 patients or 2.4% with BARC type 3b bleeding, 35 patients or
6.9% with BARC type 3a bleeding. By receiver operating characteristic curve anal-
ysis, the TEG results of ADP inhibition >80.7% had a predictive value of BARC type
3 bleeding with an area under the curve¼ 0.556 (95%CI 0.511-0.6, p¼0.045).
Binary logistic regression analysis identiﬁed ADP inhibition >80.7% (OR: 2.637,
95%CI: 1.268-5.483, p¼0.009), and two tag SNPs rs6785930 (OR: 2.305, 95%CI:
1.180-4.503, p¼0.015), rs6809699 (OR: 3.227, 95%CI: 1.587-6.558, p¼0.001)) as
signiﬁcant independent predictors of BARC type 3 bleeding in the context of gain of
function CYP2C19*17 allele. A total of 34 ischemic events occurred. However, no
signiﬁcant inﬂuence of tag SNPs of P2Y12 on the occurrence of ischemic events was
found. TEG did not predict ischemic events, either.
Conclusions: In our study population, the P2Y12 genetic locus harbors SNPs that
could have inﬂuence on bleeding events after PCI, and the ADP inhibition of TEG had
a predictive value of bleedings.
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Objectives: To assess whether NLRP3 concentration was related to atherosclerotic
severity and any speciﬁc features of coronary lesions on angiographic assessment and
if NLRP3 concentration has any prognostic value in acute coronary syndrome (ACS)
patients.
Methods: In our study we examined one hundred and twenty three (123) subjects
including 30 controls (C¼30) and 93 Acute coronary Syndrome (ACS¼93) patients.
We evaluated the association of baseline NLRP3 level with clinical presentation,
angiographic characteristics, SYNTAX score, Clinical SYNTAX score (CSS) and
Gensini score. Follow up for major adverse cardiac events (MACE) was carried out atJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/C6 months and Kaplan-Meier curves were constructed. Prognostic values of NLRP3,
GRACE score and TIMI score were determined by receiver operating characteristic
(ROC) curves.
Results: NLRP3 was found to be elevated in ACS patients (P<0.05). There was
positive correlation between NLRP3 and SYNTAX score, Clinical SYNTAX score
and Gensini score. P value was found to be 0.01 in all cases. NLRP3 was also
associated with severity of coronary disease based on number of vessels (P<0.05)
involved and the number of lesions (P<0.05) present and also on the presence or
absence of bifurcation lesions (P¼0.05). The 6 months mortality was 1.07% (1 pa-
tient), myocardial infarction 2.15% (2 patients) and unstable angina 3.22% (3 pa-
tients), target vessel revascularization was 3.22% (3 patients) and cardiac failure was
4.3% (4 patients). Receiver operating characteristic (ROC) curves of NLRP3 showed
good predictive value for MACE.
Conclusions: There are no previous studies related to correlation of NLRP3 levels and
severity of atherosclerosis. Our study showed positive correlation between NLRP3
concentration and SYNTAX score, CLINICAL SYNTAX score, GENSINI score,
Grace Score and TIMI score. Further studies are required to test the utilization of
NLRP3 in risk assessment and in selecting appropriate therapies for patients in low
and high risk groups as well as its utilization in decision making regarding the choice
of revascularization therapy.
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and endothelial function in patients with acute coronary syndrome
Zhang Zhu-Lin, Zhang Li-Zhen, Ma Xiu-Rui, Lan Wen-Yan
Shanxi Cardiovascular Hospital
Objectives: To observe and compare the effect of different dose of rosuvastatin on the
levels of serum adiponectin (APN), von Willebrand factor (vWF) and endothelial
function in patients with acute coronary syndrome (ACS).
Methods: 120 patients with acute coronary syndrome were randomly assigned to
receive 10 mg/day or 20 mg /day of rosuvastatin. The levels of serum lipids, adipo-
nectin (APN), von Willebrand factor (vWF) and dilation of the brachial artery were
assessed before the therapy, 4 weeks and 8 weeks after the therapy.
Results: All the levels of total cholesterol, low-density lipoprotein cholesterol,
triglycerides were signiﬁcantly decreased from baseline values in Rosuvastatin
10 mg/d and 20 mg/d groups, and the levels of high-density lipoprotein cholesterol
increased. After treatment, the level of APN was increased, brachial artery ﬂow-
mediated endothelium-depended dilation were improved; while the level of vWF was
decreased. These effects were more signiﬁcant with rosuvastatin for 8 weeks than
4 weeks; but there was no difference between 10 mg/d and 20 mg/d.
Conclusions: Treatment with rosuvastatin 10 mg/d and 20 mg/d could improve
abnormal serum lipids and endothelial function, increase APN, decrease vWF. The
effect was greater with rosuvastatin for 20 mg/d than 10 mg/d and 8 weeks than
4 weeks.
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Objectives: Clopidogrel is an inhibitor of platelet ADP P2Y12 receptors and plays
an important role in the prevention of stent thrombosis. Despite certain clinical
beneﬁt using this drug in patients undergoing percutaneous coronary intervention
(PCI), some patients do not attain adequate antiplatelet effects. Several studies report
that the genetic variation in CYP2C19 and ABCB1 is associated with an impaired
response to clopidogrel. This study was designed to investigate the genetic variants
of ABCB1, CYP2C9*2, CYP2C19*3, CYP3A4, CYP3A5, P2RY12 and P2Y1 on
exposure to clopidogrel (CLP), its active (clopi-H4) and inactive (CLPM) metabo-
lite, and platelet response to clopidogrel in Chinese Han population with acute
coronary syndrome.
Methods: The degree of inhibition of platelets was assessed using the light trans-
mittance aggregometry (LTA). Plasma concentrations of CLP, clopi-H4 and CLPM
were measured by HPLC-MS-MS method in 401 consecutive patients. Patients were
either on 75 mg clopidogrel-maintenance dose or received a 300 mg clopidogrel-
loading dose.
Results: In both the treatment groups, carriage of CYP2C19*2 and ABCB1 C3435T
was associated with lower exposure to clopi-H4 (P< 0.05) and thus decreased platelet
inhibition (P< 0.05), There was no signiﬁcant association between variant allele
PON1 and clopi-H4 formation or antiplatelet response to clopi-H4 in both groups (P>
0.05). CYP2C19*2 is a determinant for the formation of the active metabolite of
clopidogrel and its antiplatelet effects. Meanwhile, ABCB1 C3435T also plays an
important role in intestinal absorption of clopidogrel, which will further affect the
exposure to clopi-H4.
Conclusions: In both the treatment groups, carriage of CYP2C19*2 and ABCB1
C3435T was associated with lower exposure to clopi-H4 (P< 0.05) and thus decreased
platelet inhibition (P< 0.05), There was no signiﬁcant association between variant
allele PON1 and clopi-H4 formation or antiplatelet response to clopi-H4 in both
groups (P> 0.05). CYP2C19*2 is a determinant for the formation of the activeardiovascular Disease Clinical Research C127
